CuraTeQ Biologics receives approval for biosimilar Dazublys from MHRA
CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd., has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency for Dazublys, its trastuzumab biosimilar version.